Overview

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

Status:
Not yet recruiting

Trial end date:
2023-10-23

Target enrollment:

Participant gender:

Summary

A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia, and assess wether it affectsbody-weight associated parameters. This study is accepting male and female participants age 18 years to 65 years. This study will be conducted in approximately 6 study sites in the United States. Participation could last up to 13 weeks.

Phase:

Phase 1

Details

Lead Sponsor:

Sunovion

Treatments:

Antipsychotic Agents
Aripiprazole
Olanzapine
Quetiapine Fumarate
Risperidone